ICICI Prudential Nifty Pharma Index IDCW Reinvest Direct Plan
SIP amount
Min. ₹1,000
Lumpsum amount
Min. ₹1,000

ICICI Prudential Nifty Pharma Index IDCW Reinvest Direct Plan

NAV
₹9.7568
+1.07%
(26 May)
AUM
15 Cr
TER
0.3%
Risk
Very High Risk
Insights
Net Asset Value (NAV) is above its 200 days moving average
Asset Under Management (AUM) is in the top 25% of comparable funds
Total Expense Ratio (TER) is in the top 25% of comparable funds
In beta. Send feedback here.
Compare with other fund
1Y
+18.0%
+18.0%
+18.0%
+15.5%
NA
3Y
+32.3%
+32.3%
+32.3%
+28.2%
NA
5Y
+12.3%
+12.3%
+12.3%
+12.8%
NA
ALL
+10.5%
+10.5%
+10.5%
+12.5%
-1.9%
VOL
18.7%
18.7%
18.7%
16.9%
11.3%
TER
0.4%
0.4%
0.4%
0.2%
0.3%
AUM
₹540 Cr
₹540 Cr
₹540 Cr
₹10,615 Cr
₹15 Cr
INFO
0.56
0.56
0.56
0.74
-0.17
See fund holdings as of 30th Apr
Top holdings
Sun Pharmaceuticals Industries Ltd
24.3%
Dr Reddy's Laboratories Ltd
13.7%
Cipla Ltd Shs Dematerialised
10.9%
Divi's Laboratories Ltd
9.5%
Aurobindo Pharma Ltd
4.0%
Alkem Laboratories Ltd
3.9%
Lupin Ltd
3.9%
Torrent Pharmaceuticals Ltd
3.4%
Net Current Assets
3.3%
Zydus Lifesciences Ltd
3.0%
Top industry exposure
Healthcare
96.5%
Other information
Minimum SIP
₹1,000
Minimum lumpsum
₹1,000
Additional lumpsum
₹1,000
Portfolio turnover
24%
Lock-in period
-
Exit load
No exit load
Fund objective
The objective of the Scheme is to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index. However, there is no assurance or guarantee that the investment objective of the scheme shall be achieved.
Fund manager(s)
Kayzad Eghlim
Nishit Patel

FAQs